

Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



NEOADJUVANT

CCTG-CO32
(NEO-RT trial)
(opened 4/29/24)

Coord: P. Yang
PI: Dr. Zell
Accrual: 3/5

ADJUVANT

NRG-GI008/CIRCULATE
(ctDNA guided tx)
(opened 9/14/22)

Coord: A. Ballard
PI: Dr. Zell
Accrual: 5/10

INTRA-OPERATIVE

MOLECULAR FAILURE

UCI 20-43
(TAS102 + irinotecan)

Coord: M. Bauk
PI: Dr. Dayyani
Accrual: 14/15



1L METASTATIC

A022101

(at least 4 months of chemo once metastatic disease is confirmed)

(opened 9/21/23)

Coord: A. Ballard

PI: Dr. Eng
Accrual: 1/2

UCI 25-155

(Ivonescimab+ FOLFOX vs Bevacizumab+ FOLFOX)

Coord: TBD
PI: Dr. Dayyani
Pending activation

2L METASTATIC

ETCTN 10670

(Abemaciclib + 5-Fluorouracil)

(opened 4/8/25)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 3/8

UCI 23-85

(BA3182 + (EPCAM)/CD3 Antibody)

(opened 9/19/24)

Coord: P. Yang

PI: Dr. Valerin
Accrual: 7/18

ETCTN 10605

(ZEN-3694 + Cetuximab and Encorafenib; BRAF V600E)

(opened 1/14/26)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 0/3

3L METASTATIC

UCI 24-142

(VET3-TGI +/- pembrolizumab)

(opened 3/7/25)

Coord: TBD

PI: Dr. Uchio
Accrual: 0/4

UCI 24-93

(Fruquintinib)

(opened 5/28/25)

Coord: M. Bauk

PI: Dr. Dayyani
Accrual: 4/7

Newly Diagnosed

Advanced/Metastatic

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Neoadjuvant

UCI 21-191
 (SOC w/ ctDNA testing)
(opened 6/27/25)
 Coord: A. Ballard

PI: Dr. Dayyani
 Accrual: 8/20

UCI 23-184
 Pafolacianine for
 Imaging of Peritoneal
 Carcinomatosis
(opened 11/13/24)
 Coord: L. Mejia
 PI: Dr. Senthil
 Accrual: 7/10

ESCC

UCI 24-77
 (I-DXd)

Coord: TBD
 PI: Dr. Dayyani
Pending activation

Newly Diagnosed Metastatic

A022102
 (mFOLFIRINOX +/-
 Nivolumab vs. FOLFOX
 +/- Nivolumab)

Coord: M. Bauk
 PI: Dr. Dayyani
 Accrual: 9/14

EA2234
 (IP/IV Paclitaxel + IV 5-FU
 + LV VS SOC)
(opened 8/28/25)
 Coord: L. Mejia
 PI: Dr. Senthil
 Accrual: 4/65

UCI 21-10
 (FOLFOX + nivo + TJ033721 (anti-
 CLDN18.2 + anti-4-1BB)

Coord: M. Nguyen
 PI: Dr. Dayyani
 Accrual: 23/35

Recurrent

UCI 16-94
 (Trastuzumab, Nivolumab)
(opened 6/15/23)
 Coord: M Duron

PI: Dr. Abi-Jaoudeh
 Accrual: 35/48

UCI 24-49
 (Beamion BCGC-1:
 Oral Zongertinib +
 Trastuzumab Deruxtecan or +
 Trastuzumab Emtansine)
(opened 10/22/24)

Coord: M. Nguyen
 PI: Dr. Dayyani
 Accrual: 3/10

UCI 23-173
 (ICI in ARID1a Mu)
 Coord: TBD
 PI: Dr. Dayyani
Pending activation

HER-2

ETCTN-10358/DASH
(DS8201a + AZD6738)
Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 5/8

ETCTN-10495
(DS8201a + Neratinib)
(opened 3/5/25)
Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 2/7

UCI 24-49
(Beamion BCGC-1:
Oral Zongertinib +
Trastuzumab Deruxtecan)
(opened 10/22/24)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 3/10

KRAS

UCI 25-163
(BBO-11818)

Coord: K. Buttigieg

PI: Dr. Arter
Pending activation

Open to Accrual

EGFR

Low Accruing

CLDN18.2

UCI 21-10
(FOLFOX + nivo +
TJ033721 (anti-CLDN
18.2 + anti-4-1BB)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 23/35

Pending Activation/Suspended



Advanced Solid Tumor

<p style="text-align: center;"><u>UCI 23-85</u> (BA3182 + (EPCAM)/CD3 Antibody)</p> <p style="text-align: center; color: #ffc107;">(opened 9/19/24)</p> <p style="text-align: center;">Coord: P. Yang PI: Dr. Valerin Accrual: 7/18</p>	<p style="text-align: center;"><u>UCI 22-26</u> (Androgen and glucocorticoid receptor antagonist)</p> <p style="text-align: center;">Coord: B. Nguyen PI: Dr. Dayyani Accrual: 11/16</p>	<p style="text-align: center;"><u>ETCTN-10579</u> (ZEN003694 (ZEN-3694) + capecitabine)</p> <p style="text-align: center; color: #ffc107;">(opened 10/27/23)</p> <p style="text-align: center;">Coord: P. Yang PI: Dr. FC Lee Accrual: 2/4</p>	<p style="text-align: center;"><u>UCI 21-241</u> (ALK inhibitor NLV-655)</p> <p style="text-align: center; color: #ffc107;">(opened 10/4/22)</p> <p style="text-align: center;">Coord: A. Ballard PI: Dr. Nagasaka Accrual: 20/25</p>
<p style="text-align: center;"><u>UCI 25-16</u> (ODM-212)</p> <p style="text-align: center; color: #ffc107;">(opened 8/29/2025)</p> <p style="text-align: center;">Coord: P. Yang PI: Dr. Dayyani Accrual: 4/10</p>	<p style="text-align: center;"><u>UCI 24-138</u> (Tarlatabam in DLL3 Expressing Tumors + Neuroendocrine Neoplasms)</p> <p style="text-align: center; color: #ffc107;">(opened 10/31/2025)</p> <p style="text-align: center;">Coord: N. Ferrand PI: Dr. Park Accrual: 1/5</p>	<p style="text-align: center;"><u>ETCTN-10572</u> (Temozolomide + M1774)</p> <p style="text-align: center; color: #ffc107;">(opened 12/11/2025)</p> <p style="text-align: center;">Coord: M. Nguyen PI: Dr. Dayyani Accrual: 0/10</p>	<p style="text-align: center;"><u>UCI 25-75</u> (CRN09682- on SST2 expressing tumors)</p> <p style="text-align: center;">Coord: TBD</p> <p style="text-align: center;">PI: Dr. Dayyani <u>Pending activation</u></p>



UCI 03-03
 (Immunologic response analysis)

Coord: B. Sanchez
 PI: Dr. Imagawa
 Accrual: 336/400

UCI 23-29
 (Electroacupuncture in symptom management after CRS/HIPEC)

PI: Dr. Eng
 Accrual: 10/10

UCI 24-05
 (Rizule for Cancer-related Cognitive Impairment)

(opened 6/18/2025)
 Coord: M. Bauk
 PI: Dr. Chan
Suspended

UCI 22-55
 (ID GenomeSig for HomoRecomboDeficiency inPC & Mismatch RepairDeficiency in Microsatellite Instable CC)

(opened 3/13/2025)
 PI: Dr. Pannunzio/Dr. Valerin
 Accrual: 12/50